Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Technology evaluation: BL22, NCI.

¹Institute of Biology, Aachen, Germany. barth@molbiotech.rwth-aachen.de

Current Opinion in Molecular Therapeutics

|March 9, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tumor suppressor protein-inspired peptide for siRNA delivery and synergistic cancer therapy.

Fundamental research·2026

Same author

Carrier-Free Peptide-Daunorubicin-Small Interfering RNA Nanoassembly for Targeted Therapy of Acute Myeloid Leukemia.

Cyborg and bionic systems (Washington, D.C.)·2025

Same author

The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non-Toxic Treatment Option for Superficial Triple Negative Breast Cancer.

Cancer medicine·2025

Same author

<i>In vitro</i> anti-tumor activities of a novel recombinant immunotoxin targeting differentially overexpressed Leucine-rich repeat-containing G-protein-coupled receptor 5 in cervical cancer.

Immunopharmacology and immunotoxicology·2025

Same author

SNAP-Tag-Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light-Accessible Melanotransferrin-Expressing Melanoma and Triple-Negative Breast Cancer.

Cancer medicine·2025

Same author

Anti-CD64(scFv)-SNAP-Auristatin F: An in vitro proof of concept study for a recombinant antibody conjugate targeting CD64<sup>+</sup> acute monocytic leukemia.

European journal of medicinal chemistry·2025

BL22, a novel immunotoxin targeting CD22, shows promise for treating B-cell malignancies like lymphoma. This therapy combines an antibody fragment with a Pseudomonas exotoxin and is now in early-stage clinical trials.

Area of Science:

Oncology
Immunotherapy
Molecular Biology

Background:

B-cell malignancies represent a significant area of unmet medical need.
Current treatments for B-cell lymphomas have limitations.
Targeted therapies offer potential for improved efficacy and reduced toxicity.

Purpose of the Study:

To develop a novel targeted therapy for B-cell malignancies.
To evaluate the potential of BL22 (RFB4(dsFv)-PE38) as an anti-cancer agent.

Main Methods:

BL22 is a recombinant immunotoxin.
It comprises the Fv fragment of the anti-CD22 antibody RFB4.
This is genetically fused to a truncated Pseudomonas exotoxin A.

Main Results:

Related Experiment Videos

BL22 targets the CD22 antigen expressed on B-cells.
The disulfide-stabilized Fv fragment enhances stability and binding.
Pseudomonas exotoxin A provides cytotoxic activity.

Conclusions:

BL22 is a promising targeted immunotoxin for B-cell malignancies.
Its development is ongoing, with Phase I trials initiated for B-cell lymphoma.
Further clinical evaluation is warranted to establish its therapeutic role.